Molecular profiling of tumor tissue using targeted clinical proteomics

我们的研究结果显示了检测新诊断的非转移性癌症患者血液中肿瘤驻留蛋白的能力。为进一步阐明特定的分子表型，对单个患者的肿瘤进行深入的蛋白质组学分析。一组假定的标记物正在研究中，采用高通量技术，采用合适的免疫测定法，以测试对更大的患有这种特殊实体器官肿瘤的患者群体的普遍适用性。这种方法促进了治疗效果的最大化，毒性的最小化，并试图减少医疗经济负担。现在，进一步的研究表明，利用患者肿瘤的薄组织方法为个体患者癌症中涉及的关键蛋白质提供了一个发现平台。其中许多是药物靶点。这种新方法几乎与免疫组化（IHC）的组织和时间要求相同，但是互补的。一个主要目标是为临床试验提供一种新的研究工具，使用这种实用的方法在蛋白质水平上进行分子分析，并从患者的实际肿瘤中提取薄组织切片。

Our results have shown the ability to detect tumor residing proteins in the blood of a patient with a newly diagnosed non-metastatic cancer. In depth proteomic profiling of an individual patient's tumor for further elucidation of the particular molecular phenotype. A panel of putative markers are under investigation with high throughput techniques employing suitable immunoassays to test for general applicability to a much larger patient cohorts with this particular solid organ tumor. Such an approach facilitates maximization of therapeutic efficacy, minimization of toxicities, and an attempt to reduce medical economic burdens. Further studies have now shown that a thin-tissue approach utilizing patient tumors, provide a discovery platform for key proteins involved in the individual patient's cancer. Many of these are drug targets. This new approach is nearly identical to the tissue and time requirements of IHC (immunohistochemistry), but is complementary. A major goal is to provide a new research tool for clinical trials, using this practical approach of molecular profiling on a protein level, with thin tissue sections from the patient's actual tumor.